BioReliance subsidiary gains 4 NIH contracts

Maryland Watch

October 21, 1997

BioReliance Corp. has been awarded four federal contracts to produce viral materials for experimental gene therapy studies planned by the National Institutes of Health.

Brandon Price, chief operating officer for publicly held BioReliance of Rockville, said the contracts are worth $3.5 million. They were awarded to Magenta Corp., a BioReliance subsidiary that specializes in biotechnology contract manufacturing.

Combined, the contracts are the largest Magenta has ever received, he said.

Federal contracts represent about 10 percent of BioReliance's revenue, Price said.

Under three of the agreements, Magenta will produce viral "vectors" -- viruses that have been rendered harmless so they can be used to hold and transport genes to treat diseases.

The largest contract, worth more than $2 million, is with the NIH's National Institute of Allergies and Infectious Diseases.

The other contracts are with the NIH's National Institute of Neurological Disorders, National Eye Institute and National Institute for Dental Research.

Pub Date: 10/21/97

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.